We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Sarepta Therapeutics (SRPT) Up 19.3% Since Its Last Earnings Report?
Read MoreHide Full Article
A month has gone by since the last earnings report for Sarepta Therapeutics, Inc. (SRPT - Free Report) . Shares have added about 19.3% in that time frame.
Will the recent positive trend continue leading up to its next earnings release, or is SRPT due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Sarepta incurred a loss of 37 cents per share in the fourth quarter of 2017, narrower than the year-ago loss of 71 cents. However, the reported figure is wider than the Zacks Consensus Estimate of a loss of 31 cents.
Quarterly Details
Exondys 51, delivered solid performance in the fourth quarter. The company’s revenues came in at $57.3 million, up 24.6% sequentially, primarily owing to sales of Exondys 51. However, the top line slightly missed the Zacks Consensus Estimate of $57.38 million. In the prior-year quarter, Sarepta’s revenues totaled $5.4 million.
Research and development (R&D) expenses were $44.4 million, down 37.2% year over year. The company remunerated an up-front payment of $40.0 million to Summit Therapeutics in the year-ago quarter.
Selling, general & administrative (SG&A) expenses were $32.2 million, up 40.5% year over year, courtesy of worldwide commercial initiatives, compensation and other personnel expenses.
2017 Performance
In 2017, adjusted loss was 86 cents per share compared with $5.49 last year. The reported figure was wider than the Zacks Consensus Estimate of 77 cents.
Revenues came in at $154.6 million, which was almost in line with the Zacks Consensus Estimate of $154.67 million.
Outlook
Based on sales trends witnessed in 2017, Sarepta expects Exondys 51 sales to double in 2018.
How Have Estimates Been Moving Since Then?
It turns out, fresh estimates have trended downward during the past month. There have been three revisions higher for the current quarter compared to four lower. In the past month, the consensus estimate has shifted by 5.1% due to these changes.
At this time, SRPT has a poor Growth Score of F, however its Momentum is doing a bit better with a D. Charting a somewhat similar path, the stock was allocated a grade of F on the value side, putting it in the lowest quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Our style scores indicate investors will probably be better served looking elsewhere.
Outlook
Estimates have been trending downward for the stock and the magnitude of these revisions indicates a downward shift. Notably, SRPT has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Is Sarepta Therapeutics (SRPT) Up 19.3% Since Its Last Earnings Report?
A month has gone by since the last earnings report for Sarepta Therapeutics, Inc. (SRPT - Free Report) . Shares have added about 19.3% in that time frame.
Will the recent positive trend continue leading up to its next earnings release, or is SRPT due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Sarepta Q4 Earnings Miss, Exondys 51 Revenues Impress
Sarepta incurred a loss of 37 cents per share in the fourth quarter of 2017, narrower than the year-ago loss of 71 cents. However, the reported figure is wider than the Zacks Consensus Estimate of a loss of 31 cents.
Quarterly Details
Exondys 51, delivered solid performance in the fourth quarter. The company’s revenues came in at $57.3 million, up 24.6% sequentially, primarily owing to sales of Exondys 51. However, the top line slightly missed the Zacks Consensus Estimate of $57.38 million. In the prior-year quarter, Sarepta’s revenues totaled $5.4 million.
Research and development (R&D) expenses were $44.4 million, down 37.2% year over year. The company remunerated an up-front payment of $40.0 million to Summit Therapeutics in the year-ago quarter.
Selling, general & administrative (SG&A) expenses were $32.2 million, up 40.5% year over year, courtesy of worldwide commercial initiatives, compensation and other personnel expenses.
2017 Performance
In 2017, adjusted loss was 86 cents per share compared with $5.49 last year. The reported figure was wider than the Zacks Consensus Estimate of 77 cents.
Revenues came in at $154.6 million, which was almost in line with the Zacks Consensus Estimate of $154.67 million.
Outlook
Based on sales trends witnessed in 2017, Sarepta expects Exondys 51 sales to double in 2018.
How Have Estimates Been Moving Since Then?
It turns out, fresh estimates have trended downward during the past month. There have been three revisions higher for the current quarter compared to four lower. In the past month, the consensus estimate has shifted by 5.1% due to these changes.
Sarepta Therapeutics, Inc. Price and Consensus
Sarepta Therapeutics, Inc. Price and Consensus | Sarepta Therapeutics, Inc. Quote
VGM Scores
At this time, SRPT has a poor Growth Score of F, however its Momentum is doing a bit better with a D. Charting a somewhat similar path, the stock was allocated a grade of F on the value side, putting it in the lowest quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Our style scores indicate investors will probably be better served looking elsewhere.
Outlook
Estimates have been trending downward for the stock and the magnitude of these revisions indicates a downward shift. Notably, SRPT has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.